Generic medicines: solutions for a sustainable drug market?

P. Dylst, A. Vulto, B. Godman, S. Simoens

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business. © 2013 Springer International Publishing Switzerland.
LanguageEnglish
Pages437-443
Number of pages7
JournalApplied Health Economics and Health Policy
Volume11
Issue number5
Early online date12 Jul 2013
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Industry
Pharmaceutical Preparations
Biosimilar Pharmaceuticals
Orphan Drug Production
Medicine
Drugs
Pressure
Market access
Pharmaceuticals
Manufacturing Industry

Keywords

  • biosimilar agent
  • generic drug
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • orphan drug
  • proton pump inhibitor
  • cost control
  • drug cost
  • drug industry
  • drug marketing
  • government
  • health care access
  • health care policy
  • health care quality
  • human
  • perception
  • reimbursement
  • review
  • attitude to health
  • cost savings
  • drug costs
  • drugs, generic
  • forecasting
  • humans
  • marketing

Cite this

Dylst, P. ; Vulto, A. ; Godman, B. ; Simoens, S. / Generic medicines : solutions for a sustainable drug market?. In: Applied Health Economics and Health Policy. 2013 ; Vol. 11, No. 5. pp. 437-443.
@article{213ad7952bf342bebdf21ad515179004,
title = "Generic medicines: solutions for a sustainable drug market?",
abstract = "Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business. {\circledC} 2013 Springer International Publishing Switzerland.",
keywords = "biosimilar agent, generic drug, hydroxymethylglutaryl coenzyme A reductase inhibitor, orphan drug, proton pump inhibitor, cost control, drug cost, drug industry, drug marketing, government, health care access, health care policy, health care quality, human, perception, reimbursement, review, attitude to health, cost savings, drug costs, drugs, generic, forecasting, humans, marketing",
author = "P. Dylst and A. Vulto and B. Godman and S. Simoens",
year = "2013",
month = "10",
doi = "10.1007/s40258-013-0043-z",
language = "English",
volume = "11",
pages = "437--443",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
number = "5",

}

Generic medicines : solutions for a sustainable drug market? / Dylst, P.; Vulto, A.; Godman, B.; Simoens, S.

In: Applied Health Economics and Health Policy, Vol. 11, No. 5, 10.2013, p. 437-443.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Generic medicines

T2 - Applied Health Economics and Health Policy

AU - Dylst, P.

AU - Vulto, A.

AU - Godman, B.

AU - Simoens, S.

PY - 2013/10

Y1 - 2013/10

N2 - Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business. © 2013 Springer International Publishing Switzerland.

AB - Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business. © 2013 Springer International Publishing Switzerland.

KW - biosimilar agent

KW - generic drug

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - orphan drug

KW - proton pump inhibitor

KW - cost control

KW - drug cost

KW - drug industry

KW - drug marketing

KW - government

KW - health care access

KW - health care policy

KW - health care quality

KW - human

KW - perception

KW - reimbursement

KW - review

KW - attitude to health

KW - cost savings

KW - drug costs

KW - drugs, generic

KW - forecasting

KW - humans

KW - marketing

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84885853720&partnerID=40&md5=110c5a5d8d5b2e0e44f3f0fd14416f66

U2 - 10.1007/s40258-013-0043-z

DO - 10.1007/s40258-013-0043-z

M3 - Article

VL - 11

SP - 437

EP - 443

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 5

ER -